Bold Names The Longevity Business Is Booming, But Is There a Limit to Our Lifespan?
5 snips
Oct 18, 2024 Alex Janin, a WSJ personal health reporter specializing in the booming longevity business, joins Amy Dockser Marcus, a health and science reporter focused on aging research. They dive into the $43 billion longevity industry, discussing trends and consumer demand for life-extending products. They explore the debate over whether humans can live to 100, revealing scientific skepticism about lifespan limits. The conversation highlights the balance between optimistic wellness claims and biological realities, addressing how healthy habits can influence longevity.
AI Snips
Chapters
Transcript
Episode notes
Longevity Business Booming
- The longevity business is booming, with $43 billion invested globally in the last decade.
- Consumer interest in healthy aging products and services is also rising.
Longevity Claims Debated
- The longevity business assumes we can extend lifespan and healthspan, but this is debatable.
- Reporter Amy Dockser Marcus notes the technology and medical claims are under debate.
Longevity Business Scope
- The longevity business includes lifestyle and medical aspects, from spas and gyms to concierge medicine.
- Biohackers experiment with off-label drugs like metformin and rapamycin, hoping to extend lifespan.